Swedish Orphan Biovitrum has a total of 1852 patents globally, out of which 822 have been granted. Of these 1852 patents, more than 46% patents are active. The USA is where Swedish Orphan Biovitrum has filed the maximum number of patents, followed by Australia and Europe (EPO). Parallelly, Sweden seems to be the main focused R&D centre of Swedish Orphan Biovitrum.
Swedish Orphan Biovitrum was founded in the year 1939. Based in Stockholm, Sweden, the business is a global biopharmaceutical organisation that specialises in immunology, haematology, and speciality care treatments. As of May 2023, Swedish Orphan Biovitrum has a market cap of $7.37 Billion.
Do read about some of the most popular patents of Swedish Orphan Biovitrum which have been covered by us in this article and also you can find Swedish Orphan Biovitrum patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Swedish Orphan Biovitrum patent portfolio.
How many patents does the CEO of Swedish Orphan Biovitrum have?
The CEO, Guido Oelkers, has 0 patents.
How many patents does Swedish Orphan Biovitrum have?
Swedish Orphan Biovitrum has a total of 1852 patents globally. These patents belong to 339 unique patent families. Out of 1852 patents, 854 patents are active.
How Many Patents did Swedish Orphan Biovitrum File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Swedish Orphan Biovitrum Applications Filed | Swedish Orphan Biovitrum Patents Granted |
| 2022 | 2 | 9 |
| 2021 | 10 | 23 |
| 2020 | 9 | 21 |
| 2019 | 20 | 33 |
| 2018 | 50 | 35 |
| 2017 | 27 | 12 |
| 2016 | 67 | 41 |
| 2015 | 68 | 16 |
| 2014 | 29 | 28 |
| 2013 | 38 | 23 |
| 2012 | 66 | 12 |
| 2011 | 9 | 27 |
Which Swedish Orphan Biovitrum Drug Patents are Expiring in the Next 10 Years?
The patent no. US9301932B2 which is expiring in Feb, 2033, describing to develop a formulation for nitisinone, incorporating the active agent 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione. Investigate its synthesis and biological activity.
Given below is the list of few drugs patented by Swedish Orphan Biovitrum accompanied by a patent relevant to the drug which will be available for generic drug manufacturing and usage within the next/upcoming 10 years for treatment of various diseases and disorders.
| Drug Name | Patent Number | Patent Title | Patent Expiration |
| Orfadin | US9301932B2 | Liquid Pharmaceutical Composition… | Feb, 2033 |
Interested in knowing about Swedish Orphan Biovitrum’s Drug Patents Expiring in the next 10 years?
How many Swedish Orphan Biovitrum patents are Alive/Dead?
How Many Patents did Swedish Orphan Biovitrum File in Different Countries?
Countries in which Swedish Orphan Biovitrum Filed Patents
| Country | Patents |
| United States Of America | 180 |
| Australia | 144 |
| Europe | 122 |
| Japan | 88 |
| Canada | 82 |
| China | 68 |
| Hong Kong (S.A.R.) | 66 |
| Germany | 65 |
| Sweden | 57 |
| Norway | 53 |
| Denmark | 52 |
| India | 52 |
| Israel | 51 |
| Korea (South) | 50 |
| Austria | 49 |
| Singapore | 43 |
| Brazil | 42 |
| South Africa | 37 |
| Portugal | 37 |
| Spain | 34 |
| Mexico | 33 |
| New Zealand | 29 |
| Eurasia | 22 |
| Poland | 22 |
| Russia | 20 |
| Indonesia | 20 |
| Slovenia | 20 |
| Philippines | 14 |
| Serbia | 12 |
| Chile | 11 |
Where are Research Centres of Swedish Orphan Biovitrum Patents Located?
10 Best Swedish Orphan Biovitrum Patents
US6599724B1 is the most popular patent in the Swedish Orphan Biovitrum portfolio. It has received 75 citations so far from companies like Novo Nordisk, Arecor Limited, and Baxalta Incorporated.
Below is the list of 10 most cited patents of Swedish Orphan Biovitrum:
| Publication Number | Citation Count |
| US6599724B1 | 75 |
| US6472515B1 | 74 |
| WO2008025799A1 | 72 |
| WO2003039547A1 | 71 |
| WO2004063156A1 | 69 |
| US6733753B2 | 68 |
| US20060142269A1 | 66 |
| WO2008028662A1 | 61 |
| WO2003097636A1 | 61 |
| WO2002092585A1 | 60 |